Renovaro Inc. Reports Board Changes and Compensation Updates
Ticker: LNAI · Form: 8-K · Filed: Nov 21, 2024 · CIK: 1527728
| Field | Detail |
|---|---|
| Company | Renovaro Inc. (LNAI) |
| Form Type | 8-K |
| Filed Date | Nov 21, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation
TL;DR
Renovaro Inc. shook up its board and exec pay structure as of Nov 15, 2024.
AI Summary
Renovaro Inc. announced on November 15, 2024, a change in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory plans. Specific details regarding the individuals involved and the financial impact of these changes are outlined within the report.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial outlook, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board and executive changes can indicate internal shifts that may affect company direction and stability.
Key Players & Entities
- Renovaro Inc. (company) — Registrant
- November 15, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific roles have been affected by the departure of officers or directors?
The filing indicates the departure of certain officers and directors, but the specific roles are detailed within the full report.
Who are the newly elected directors?
The election of new directors is reported, with their identities and backgrounds available in the complete filing.
What are the key changes in compensatory arrangements?
The report addresses updates to compensatory arrangements for certain officers, with specific details provided in the document.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on November 15, 2024.
What is the primary business of Renovaro Inc. according to the filing?
Renovaro Inc. is classified under Pharmaceutical Preparations (SIC code 2834).
Filing Stats: 384 words · 2 min read · ~1 pages · Grade level 12.7 · Accepted 2024-11-21 16:19:41
Key Financial Figures
- $0.0001 — ch Registered Common Stock, par value $0.0001 per share RENB The Nasdaq Stock Mar
Filing Documents
- e6162_8k.htm (8-K) — 26KB
- 0001731122-24-001842.txt ( ) — 197KB
- renb-20241115.xsd (EX-101.SCH) — 3KB
- renb-20241115_lab.xml (EX-101.LAB) — 33KB
- renb-20241115_pre.xml (EX-101.PRE) — 24KB
- e6162_8k_htm.xml (XML) — 4KB
02 Departure of Directors or Certain Officers;
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Chief Operating Officer Resignation On November 15, 2024, Francois Binette PhD, Renovaro Inc.'s Chief Operating Officer, tendered his resignation as Chief Operating Officer, effective November 22, 2024.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RENOVARO INC. By: /s/ Simon Tarsh Name: Simon Tarsh Title: Interim Chief Financial Officer Date: November 21, 2024